Literature DB >> 8933772

Steroid-resistant asthma: evaluation and management.

S R Nimmagadda1, J D Spahn, D Y Leung, S J Szefler.   

Abstract

LEARNING
OBJECTIVES: Reading this article will reinforce the reader's knowledge of the definition, pathophysiology, differential diagnosis, and treatment of the steroid-resistant asthmatic patient. DATA SOURCES: Prospective and retrospective data from the authors' experience were evaluated. In addition, a Medline database was searched from 1981, using the key words "asthma," "glucocorticoids," and "glucocorticoid resistance" with the restrictions of English language and human subjects. Relevant articles referenced in retrieved sources and current texts on severe asthma were also utilized. STUDY SELECTION: Data source abstracts, pertinent articles, and book chapters meeting the objectives were critically reviewed.
RESULTS: Although rare, individuals with steroid-resistant asthma are often the most difficult-to-manage asthmatic patients in that they have severe disease yet fail to respond to glucocorticoids. To make the diagnosis of steroid-resistant asthma, the patient must fail to respond to a 7 to 14-day course of daily prednisone as measured by less than a 15% improvement in morning prebronchodilator FEV1 following the glucocorticoid course. Ongoing inflammation is thought to play a major role in the pathogenesis of steroid-resistant asthma, and recent studies have demonstrated diminished glucocorticoid receptor to glucocorticoid, or diminished glucocorticoid receptor to DNA binding as possible mechanisms for diminished glucocorticoid responsiveness. Alternative asthma therapies such as methotrexate, cyclosporine, and intravenous gammaglobulin are often used in this group of asthmatic patients.
CONCLUSIONS: The patient with steroid-resistant asthma presents several challenges. These individuals often display many of the sequelae of long-term systemic glucocorticoid use while achieving little therapeutic benefit. Prior to making the diagnosis of steroid-resistant asthma, diseases that can contribute to poor control of asthma must be ruled out, and noncompliance issues addressed. Alternative asthma therapies are often used; however, they also carry the potential for adverse effects, and have not been thoroughly studied in this population of asthmatic patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8933772     DOI: 10.1016/S1081-1206(10)63332-7

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  6 in total

Review 1.  Asthma that is unresponsive to usual care.

Authors:  Kenneth R Chapman; Andrew McIvor
Journal:  CMAJ       Date:  2009-10-13       Impact factor: 8.262

2.  Glucocorticoid-resistant Bronchial Asthma.

Authors:  K S Brar
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Ozone-Induced Oxidative Stress, Neutrophilic Airway Inflammation, and Glucocorticoid Resistance in Asthma.

Authors:  Chioma Enweasor; Cameron H Flayer; Angela Haczku
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

4.  Questioning Cause and Effect: Children with Severe Asthma Exhibit High Levels of Inflammatory Biomarkers Including Beta-Hexosaminidase, but Low Levels of Vitamin A and Immunoglobulins.

Authors:  Amali E Samarasinghe; Rhiannon R Penkert; Julia L Hurwitz; Robert E Sealy; Kim S LeMessurier; Catherine Hammond; Patricia J Dubin; D Betty Lew
Journal:  Biomedicines       Date:  2020-10-06

Review 5.  Glucocorticoid Insensitivity in Asthma: The Unique Role for Airway Smooth Muscle Cells.

Authors:  Patricia Ramos-Ramírez; Omar Tliba
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

6.  Effects of genetic polymorphisms in Vitamin D metabolic pathway on Vitamin D level and asthma control in South Indian patients with bronchial asthma.

Authors:  Manju Rajaram; Sandhiya Selvarajan; Revathy Neelamegan; Sadishkumar Kamalanathan; Vikneswaran Gunaseelan; Alphienes Stanley Xavier; Saibal Das; Vignesh Karthikeyan; Vinodkumar Saka; Adithan Chandrasekaran
Journal:  Lung India       Date:  2019 Nov-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.